Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chlamydiae: exotic and ubiquitous

J Schachter

    The Western Journal of Medicine
    |March 1, 1980
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285].

    Annals of oncology : official journal of the European Society for Medical Oncology·2022
    Same author

    Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same journal

    Does daily use of sunscreen or beta-carotene supplements prevent skin cancer in healthy adults?

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    Same journal

    [Not Available].

    The Western journal of medicine·2008
    See all related articles